Armata Pharmaceuticals, Inc., a biotechnology company dedicated to developing bacteriophage therapeutics for challenging bacterial infections, has announced the receipt of an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense. This funding is part of a larger award currently totaling $26.2 million, received through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command, aimed at supporting the clinical development of Armata's phage candidate, AP-SA02. The funding will facilitate the Phase 2a study closeout activities and preparations for an end-of-phase 2 meeting with the U.S. Food and Drug Administration. This continued support underscores the DoD's commitment to advancing AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.